P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

  • November 2021 •
  • 70 pages •
  • Report ID: 6189469 •
  • Format: PDF
P2X Purinoceptor 3 (P2RX3) - Drugs in Development, 2021

Summary
P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology and Women’s Health which include indications Chronic Cough, Pain, Cough, Neuropathic Pain (Neuralgia), Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer’s Disease, Diabetic Neuropathic Pain, Endometriosis, Insomnia, Low Back Pain, Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma and Overactive Bladder.

The latest report P2X Purinoceptor 3 - Drugs In Development, 2021, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3) Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.